Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LIPC | P11150 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.32 |
| ▸ | MAT2A | P31153 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.31 |
| ▸ | CETP | P11597 | 4/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6328734 | 1.00 | LIPG (0.34) | LIPGALDH1A1HTTSMN1; SMN2LIPC | |
| SCHEMBL6333280 | 0.79 | NPC1 (0.32) | — | |
| SCHEMBL6333278 | 0.79 | NPC1 (0.32) | — | |
| SCHEMBL8492233 | 0.79 | CES2 (0.50) | LIPGALDH1A1KDM4EPOLBNPSR1 | |
| SCHEMBL8494935 | 0.78 | KMT2A (0.39) | KDM4ENPSR1MAT2A | |
| SCHEMBL8684077 | 0.78 | KMT2A (0.39) | KDM4ENPSR1MAT2A | |
| SCHEMBL6324056 | 0.78 | — | — | |
| SCHEMBL6324050 | 0.78 | — | — | |
| SCHEMBL6831342 | 0.77 | ALDH1A1 (0.34) | ALDH1A1HTTSMN1; SMN2POLBCCR2 | |
| SCHEMBL6332863 | 0.77 | ALDH1A1 (0.34) | ALDH1A1HTTSMN1; SMN2POLBCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936570-B2 | Tetrazolinone derivatives | NIHON BAYER AGROCHEM, K.K. (JP) | 2005-08-30 | — | — | US | disclosed |
| US-20040242895-A1 | Novel tetrazolinone derivatives | YANAGI AKIHIKO (JP) | 2004-12-02 | — | — | US | disclosed |
| US-6790810-B2 | Tetrazolinone derivatives | NIHON BAYER AGROCHEM K.K. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20040102635-A1 | Novel tetrazolinone derivatives | YANAGI AKIHIKO (JP) | 2004-05-27 | — | — | US | disclosed |
| US-6624121-B1 | Exemplified by 2-cyano-3-cyclopropyl-1-(3-((4-cyclopropyl-4,5-dihydro-5-oxo-1H-tetrazol-1 -yl)methyl)-2, 4-dichlorophenyl)propan-1,3-dione | NIHON BAYER AGROCHEM K.K. (JP) | 2003-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102635-A1 | Novel tetrazolinone derivatives | CBR1, CBR3, CYP1B1 | LIPG 4773/4885ALDH1A1 225/4885HTT 1812/4885 |
| US-20040242895-A1 | Novel tetrazolinone derivatives | CBR3, CBR1, CYP1B1 | LIPG 4777/4885ALDH1A1 226/4885HTT 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.